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Abstract
Background
Despite evidence of chemotherapy’s ability to cure or comfort those with colon cancer, nearly
half of such Americans do not receive it. African Americans (AA) seem particularly
disadvantaged. An ethnicity by poverty by health insurance interaction was hypothesized
such that the multiplicative disadvantage of being extremely poor and inadequately insured is
worse for AAs than for non-Hispanic white Americans (NHWA).

Methods
California registry data were analyzed for 459 AAs and 3,001 NHWAs diagnosed with stage
II to IV colon cancer between 1996 and 2000 and followed until 2011. Socioeconomic data
from the 2000 census categorized neighborhoods: extremely poor (≥ 30% of households
poor), middle (5-29% poor) and low poverty (< 5% poor). Participants were randomly
selected from these poverty strata. Primary health insurers were Medicaid, Medicare, private
or none. Chemotherapy rates were age and stage-adjusted and comparisons used standardized
rate ratios (RR). Logistic and Cox regressions, respectively, modeled chemotherapy receipt
and long term survival.

Results
A significant 3-way ethnicity by poverty by health insurance interaction effect on
chemotherapy receipt was observed. Among those who did not live in extremely poor
neighborhoods and were adequately insured privately or by Medicare, chemotherapy rates did
not differ significantly between AAs (37.7%) and NHWAs (39.5%). Among those who lived
in extremely poor neighborhoods and were inadequately insured by Medicaid or uninsured,
AAs (14.6%) were nearly 60% less likely to receive chemotherapy than were NHWAs
(25.5%, RR = 0.41). When the 3-way interaction effect as well as the main effects of poverty,
health insurance and chemotherapy was accounted for, survival rates of AAs and NHWAs
were the same.

Conclusions
The multiplicative barrier to colon cancer care that results from being extremely poor and
inadequately insured is worse for AAs than it is for NHWAs. AAs are more prevalently poor,
inadequately insured, and have fewer assets so they are probably less able to absorb the
indirect and direct, but uncovered, costs of colon cancer care. Policy makers ought to be
cognizant of these factors as they implement the Affordable Care Act and consider future
health care reforms.

Keywords
Health insurance, Uninsured, Underinsured, Poverty, Colon cancer, Chemotherapy, African
American, Ethnicity, Health care reform, California, United States

Background
Chemotherapy provided after surgical resection is beneficial for many with non-localized
colon cancer. Survival benefits are large for many with advanced, but non-metastasized, stage
III disease and smaller, but still significant for some with stage II disease [1-3]. There are
probably even small survival benefits of chemotherapy for people with metastasized, stage IV
colon cancer, in addition to its clear palliative benefits [4]. Yet nearly half of all such people
in the United States do not receive chemotherapy with the intention to either cure or comfort
[5]. Moreover, chemotherapy access may be affected by social and economic characteristics
such as race or ethnicity, and income and health insurance adequacy. African Americans
(AA), who are also poorer and less adequately insured, on average, than non-Hispanic white

Americans (NHWA), seem particularly disadvantaged [6,7]. They are less likely to receive
adjuvant chemotherapy and this can explain much of their survival disadvantage [5,8-10].
Social and health care systemic factors seem most implicated in this racial divide for the
following reasons. First, clinical studies of equal-access health care systems within the US
have consistently observed similar chemotherapy and survival rates among AAs and NHWAs
with colon cancer [11-14]. Second, colon cancer chemotherapy rates seem to be much higher
in Canada than in the US [15,16]. Third, recent population-based studies of colon cancer care
in California and Ontario suggested that people of color, including black people of various
ethnic backgrounds, with colon cancer are much better served in California [16-18].
Moreover, health insurance inadequacies in the US versus universal coverage of medically
necessary care in Canada largely explained the between-country divide. Being uninsured or
insured by Medicaid has been consistently found to be less adequate than being insured by
Medicare or by a private insurer [5,17,18]. Fourth, this field’s research syntheses allow for
the conclusion that socioeconomic status (SES) and treatment differences largely explain
observed AA-NHWA survival differences [5,8-10]. The fact that they have largely, but not
completely accounted for racial differences with social-systemic factors suggests the
plausibility of at least one of their causes being biological. For example, AA and NHWA
patients may differ on oncogene-based tumor characteristics that affect survival directly or
indirectly, through their effects upon clinicians’ decisions to prescribe chemotherapies.
Modest equivocal differences between racialized groups on colon tumor grade [8], however,
suggest that, though possible, this explanation for the differential uptake of chemotherapy and
survival differences between AAs and NHWAs is improbable.
In attempting to account for SES, this field’s population-based studies have typically used
census data to define low-income neighborhoods. However, their lowest income
neighborhoods only ranged from 10% to 20% poor. They therefore had limited power to
study colon cancer care among the “truly disadvantaged” [19] who live, for example, in
America’s poorest neighborhoods where 30% to 40% or more of households have incomes
below the poverty line [19-21]. Consequently, they probably did not account for residual
confounding. That is, their AA participants probably had substantially lower incomes than
their NHWA counterparts, even in the lowest income neighborhoods studied [22,23]. This
field also seems limited by its focus on the mere main effects of race/ethnicity, SES and
health insurance. Recognizing that it is important to analyze different racial/ethnic minority
groups uniquely, our previous research on breast cancer care among Mexican American
women leads us to anticipate complex interactions of ethnicity, poverty and health insurance
status [24-26]. We were recently presented with a serendipitous opportunity to systematically
replicate that notion among AAs with colon cancer.
We oversampled people with colon or breast cancer in the highest poverty neighborhoods of
California for other primary studies [17,18,24]. This necessarily meant that we also
oversampled AAs. Secondary to our original study’s intentions we had the opportunity to
compare the chemotherapy and survival experiences of AAs and NHWAs with colon cancer
while providing more control for residual confounding by SES than previous studies had.
This field’s historical-theoretical context strongly suggests multiplicative, rather than additive
disadvantages of being poor and inadequately insured among AAs. That is, the combined
effects of being poor and of being uninsured or underinsured on colon cancer care are
probably worse for AAs than for NHWAs. Therefore, we hypothesize a 3-way ethnicity by
poverty by health insurance interaction on the receipt of chemotherapy. Secondarily, we
hypothesize that this complex interaction, along with the main effects of poverty, health

insurance adequacy and treatment access, will now completely explain any observed AANHWA survival differences.

Methods
Six thousand, three hundred people who were diagnosed with colon cancer between 1996 and
2000 were randomly selected from the California Cancer Registry (CCR) that was joined to
the 2000 census by census tracts [17,18,27]. The original sample was also stratified by SES
(extremely poor neighborhoods where 30% or more of the households were poor, 5% to 29%
or less than 5% poor) and place (large or smaller urban or rural). This secondary analysis
excluded localized, stage I cancers for which chemotherapy is not indicated as well as people
of other racial or ethnic backgrounds [28,29]. This study then analyzed colon cancer care
among 459 AAs (also non-Hispanic) and 3,001 NHWAs with stage II to IV disease.
A logistic regression model was used to test the 3-way ethnicity (AA vs. NHWA) by poverty
(extremely poor or not) by health insurance adequacy (uninsured or Medicaid insured vs.
privately or Medicare insured) interaction in predicting binary chemotherapy receipt [30].
Odds ratios (OR) and 95% confidence intervals (CI) were estimated from regression
statistics. AA study participants were younger (M = 67.4, SD = 13.9), on average, than the
NHWA participants (M = 70.9, SD = 13.0), F (1, 3,458) = 28.39, p < .05. Therefore, all rates
were internally age-adjusted and reported as percentages (rates per 100). Chemotherapy rates
were also stage-adjusted as clinical indication and prescription rates differ significantly for
stage II, III and IV disease. Then standardized rate ratios (RR) were reported for critical
between-group comparisons with 95% CIs derived from the Mantel-Haenszel χ2 test.
Standardized rate difference (RD) indices were also used to further aid the interpretation of
practical-clinical significance. The hypothesis that the main and interacting effects of
ethnicity, poverty, health insurance and chemotherapy access would completely explain any
observed AA-NHWA survival difference was tested with unadjusted and adjusted Cox
proportional hazards regression models [31]. All participants were minimally followed for 10
years, from the date of their diagnosis until January 1, 2011. Hazard ratios (HR) and 95% CIs
were estimated from regression statistics. Other methodological details have been reported
[17,18,27]. This study was reviewed and cleared by the University of Windsor research ethics
board.

Results
Description of AA and NHWA samples
Unadjusted descriptive profiles of the AA and NHWA samples are displayed in Table 1. The
statistically significant comparisons seem consistent with existing knowledge. AAs were
much more likely to live in high poverty neighborhoods and seemed more likely to be either
uninsured or to be insured by Medicaid. Interestingly, oversampling from poor
neighborhoods seems to have provided ample control for SES and biological characteristics.
Median annual household incomes among extremely poor AAs ($22,600) and NHWAs
($23,650), though significantly different in a statistical sense, were actually quite similar.
Overall, the two ethnic groups did not differ significantly on either tumor grade or on stage of
disease at diagnoses. AAs seemed somewhat less likely to receive chemotherapy.

Table 1 Socio-demographic and clinical characteristics of African American and nonHispanic white American colon cancer patients in California, 1996-2000
African American, No. (%)
Age at diagnosis,** y
25 - 59
129
28.1
60 - 69
99
21.6
70 - 79
138
30.1
≥ 80
93
20.3
Women**
275
59.9
Neighborhood poverty prevalence,**%
<5
31
6.8
5 - 29
76
16.6
≥ 301
352
76.7
Primary health insurers**
Private
194
42.3
Medicare
201
43.8
Medicaid
36
7.8
Uninsured
28
6.1
Stage at diagnosis
II
184
40.1
III
132
28.8
IV
143
31.2
Tumor grade
I
31
7.4
II
286
68.4
III or IV2
101
24.2
41
8.9
Missing data*
Examined 12 or more RLN3
124
40.4
Missing data
9
2.8
145
31.7
Received Chemotherapy*
Missing data
2
0.4

Non-Hispanic White, No. (%)
563
629
980
829
1,574

18.8
21.0
32.7
27.6
52.4

1,240
1,131
630

41.3
37.7
21.0

1,409
1,391
72
129

47.0
46.4
2.4
4.3

1,270
927
804

42.3
30.9
26.8

192
1,863
752
194
939
67
1,124
9

6.8
66.4
26.8
6.5
44.1
3.0
37.6
0.3

Note. RLN, Regional lymph nodes.
1
Median annual household income for extremely poor AA ($22,600) and NHWA ($23,650) subsamples;
median test [46], χ2 (1, N = 982) = 5.51, p < .05.
2
Only 23 (0.7%) of the tumors were undifferentiated or grade IV.
3
Stage IV metastasized disease excluded.
*
p < .10 and ** p < .05 for between-ethnic group difference (χ2 test).

Age-adjusted comparisons served to clarify the socioeconomic divide between AAs and
NHWAs. AA patients (77.3%) were nearly four times as likely as NHWA patients (20.9%) to
live in extremely poor neighborhoods (RR = 3.70, 95% CI 3.33, 4.11), they were nearly twice
as likely to be either uninsured to Medicaid-insured (12.0% vs. 6.9%, RR = 1.74, 95% CI
1.31, 2.31) while they were 17% less likely to be privately insured (39.4% vs. 47.5%, RR =
0.83, 95% CI 0.74, 0.93). While one of every nine AA study participants (11.3%) suffered the
multiplicative disadvantage of living in an extremely poor neighborhood and being
inadequately insured, only one of every 36 NHWA participants was so disadvantaged (RR =
4.03, 95% CI 2.97, 5.48). Finally, the AA patients were 26% less likely to receive
chemotherapy (age- and stage-adjusted rates of 28.2% vs. 38.2%, RR = 0.74, 95% CI 0.63,
0.85). It should be noted that nearly all (99.0%) of the patients with stage II or III disease
received surgical resections. Fewer with stage IV disease had surgery, and among them fewer

of the AA (60.1%) than NHWA (73.1%) patients were so treated (RR = 0.82, 95% CI 0.73,
0.93). However, surgery refusal rates (5.5%) were identical for the AAs and NHWAs with
metastasized disease.

Ethnicity by poverty by health insurance interaction
As hypothesized, a significant 3-way ethnicity by poverty by health insurance interaction was
detected (OR = 1.46, 95% CI 1.04, 2.06) with an age, stage and grade-adjusted logistic
regression on chemotherapy receipt that included the well-known main disadvantaging
effects of being AA (OR = 0.64, 95% CI 0.48, 0.84), extremely poor (OR = 0.70, 95% CI
0.58, 0.85) and inadequately insured (OR = 0.60, 95% CI 0.40, 0.89). Neither main or
interacting effects of gender nor the number of region lymph nodes examined entered the
model. As interpretation of the 3-way interaction effect’s point-estimate (OR = 1.46) is not
intuitive, the interaction is practically depicted in Table 2. At the top of the table it can be
seen that among those who did not live in extremely poor neighborhoods and were
adequately insured, chemotherapy rates did not differ significantly between AAs and
NHWAs. Moving down the table one sees that among those with one of two disadvantages,
AAs were 20% less likely to receive chemotherapy (RR = 0.80). And at the bottom of the
table we see that among the multiply disadvantaged, the disadvantaging effect on
chemotherapy access appeared multiplicative. Among them AAs were nearly 60% less likely
to receive chemotherapy than were NHWAs (RR = 0.41). One should note that chemotherapy
refusal rates did not differ between these, most disadvantaged, AA (5.9%) and NHWA
(6.3%) patients; χ2 (1, N = 130) = 0.01, p = .92.
Table 2 Effects of the interaction of ethnicity, neighborhood poverty and health
insurance on chemotherapy receipt in California, 1996-2000
No.1
< 30% Poor & Adequately Insured
Non-Hispanic white American
2,249
African American
94
Intermediate Groups3
Non-Hispanic white American
673
African American
314
≥ 30% Poor & Inadequately Insured
Non-Hispanic white American
79
African American
51

Rate

RR2

(95% CI)

NHWA-AA
Chemotherapy RD

.395
.377

1.00
0.95

(0.75, 1.20)

1.8%

.345
.277

1.00
0.80

(0.65, 0.98)

6.8%

.352
.146

1.00
0.41

(0.22, 0.78)

20.6%

Notes. NHWA, Non-Hispanic white American; AA, African American; RR, Standardized rate ratio; RD, Standardized rate
difference; CI, Confidence interval. All rates were directly age and stage-adjusted using this study’s combined AA-NHWA
population of cases as the standard.
1
Number of incident colon cancer cases.
2
A rate ratio of 1.00 was the within-ethnic group baseline.
3
Included those who lived in extremely poor neighborhoods, but were adequately insured or those who lived in less poor
neighborhoods, but were inadequately insured.

The multiplicative disadvantage of extremely poor and inadequately insured AAs is depicted
in another, perhaps more clinically telling way, in the table’s right column. The NHWA-AA
RD on chemotherapy receipt was 1.8% among the most advantaged group. While the RD of
20.6% among the most disadvantaged group was more than a 10-fold multiple of that
baseline difference. Such seems indicative of a huge chemotherapy access barrier. The
support we found for our secondary hypothesis strongly suggests though that it can be
effectively remediated. An age, gender, stage and grade-adjusted Cox regression on survival

found that the AA patients were much more likely to die over the 10 year follow-up period
(HR = 1.26, 95% CI 1.13, 1.42). When another model was run in which the main effects of
poverty, health insurance and chemotherapy as well as the interaction effect of ethnicitypoverty-health insurance were entered, AAs and NHWAs experienced identical risks of death
(HR = 1.01, 95% CI 0.71, 1.43).

Discussion
First, this field’s established ethnicity-outcome relationships were systematically replicated
among historical cohorts of AAs and NHWAs with non-localized colon cancer. This study’s
AA participants were about 25% less likely to receive chemotherapy and about 25% more
likely to die over the 10 years following their diagnosis than were its NHWA participants.
Next, this field’s well-known main predictive effects were replicated. AAs, those who lived
in extremely poor neighborhoods and those who were inadequately insured were all
significantly less likely than NHWAs, the less poor or the adequately insured to receive
chemotherapy and so more likely to die sooner. Then an ethnicity by poverty by health
insurance interaction on chemotherapy receipt was discovered. This study’s central original
finding, the 3-way interaction is evidence of the multiplicative disadvantage experienced by
extremely poor and inadequately insured AAs seeking colon cancer care. Among relatively
advantaged people, AA and NHWA chemotherapy rates differ little, if at all (< 2%).
However, among the multiply disadvantaged extremely poor and inadequately insured, the
AA-NHWA chemotherapy RD (> 20%) could, we think, be fairly characterized as huge in
terms of both its clinical and human significance. Finally, controlling for residual SES
confounding by oversampling from extremely poor neighborhoods and further controlling for
demographic and biological differences through mathematical modeling, we discovered that
the main and interacting effects of poverty, health insurance adequacy and treatment access
can completely account for the typically observed AA-NHWA survival differences. After we
accounted for such social forces, the survival experiences of the AA and NHWA colon
cancer patients we studied were essentially identical.
Two-way poverty by health insurance interactions have previously been observed in studies
of breast and colon cancer care among NHWAs [18,24,25]. The beneficial effects of health
insurance were observed to be strongest in low poverty neighborhoods. It was theorized that
the effectiveness of health insurance programs was positively impacted by the availability of
other key resources. In more affluent neighborhoods, where social and economic capital
abounds, most people with cancer seemed able to absorb the indirect (time lost from work,
recuperation, transportation and others) and direct, but additional uncovered, out-of-pocket
costs of care (co-insurance and co-payments). Within high poverty neighborhoods on the
other hand, relatively lacking in such capital reserves, health insurance programs seemed to
be much less effective. Such extremely poor people were probably much less able to pick-up
the co-insurance costs and co-payments that are prevalent in American cancer care. The 3way ethnicity-poverty-health insurance interaction observed in this study may be thought of
as an extension of the previously observed 2-way poverty-health insurance interaction. It
strongly suggests that the 2-way interaction’s effect is stronger for AAs. Their relative lack of
capital reserves could explain this differential ethnic effect [32,33]. We saw that this study’s
oversampling from extremely poor neighborhoods seemed to fairly well control AA-NHWA
differences on depth of impoverishment [22,23], at least in terms of their annual household
incomes that only differed by about $1,000. However, a contemporaneous analysis found that
among the poorest households in America, NHWAs typically held $10,000 worth of equity,
while AAs typically had no assets at all [7]. It seems probable that their lack of capital

reserves operates to further potentiate the disadvantages already experienced by extremely
poor and inadequately insured AAs as they try to purchase chemotherapeutic and other colon
cancer care services.

Practical—clinical and policy—significance
Approximately 13,300 AAs are diagnosed with colon cancer each year [34,35].
Unfortunately, they quite commonly live in poor, often extremely poor, neighborhoods (one
of every four or five households) and are also commonly uninsured or underinsured (one of
every three or four households) [6,20]. Applying this study’s chemotherapy estimates to these
population parameters and social exposures we estimate that each year slightly more than
1,500 AAs with colon cancer are treated less optimally than are NHWAs of similar ages with
colon cancers of similar stages and grades [36]. That represents 22,500 relatively
undertreated AAs with colon cancer during the 15 years that preceded passage of the Patient
Protection and Affordable Care Act, so-called Obamacare. This striking inequity is probably
only the tip of the iceberg of AA disadvantages as colon cancer accounts for less than 3% of
the burden of disease in the US [37]. One should hope that as Obamacare is rolled out and
provides millions more Americans with health insurance that it will also diminish the racial
and ethnic divides that presently exist in American health care. Such will probably depend
largely upon the adequacy of the new health insurances it provides. Health care reformers
need to account for the fact that even covered health care, especially for such diseases as
colon cancer [38], has myriad out-of-pocket costs. Health insurance programs that serve to
minimize such costs will necessarily be more effective than those that do not.

Potential limitations
This study could have been limited by incomplete information on chemotherapy. Because
chemotherapy is most often received as an outpatient it can be more challenging for cancer
registries to survey. For the following reasons we think it not a potent alternative explanation.
First, the CCR has been demonstrated to be mostly complete (81% to 84%) on chemotherapy
and errors have been demonstrated not to differ significantly by race/ethnicity or income
[39,40]. Second, missing chemotherapy data was modest and did not differ between this
study’s AA and NHWA samples. Third, analyses of health insurance, surgeries and survival
were unlikely to have been affected [40-43] and modest errors very likely did not differ by
socioeconomic factors [41]. Such nondifferential errors suggest that any bias would probably
have been toward the null [44,45]. That is, the magnitude of this study’s observed AA
disadvantages may, in fact, be underestimates of the truth.
This study’s findings could also have been confounded by comorbid differences between its
AA and NHWA samples. The CCR did not code comorbidities that are well known to be
associated with socioeconomic factors, colon cancer care and survival [5]. However, AAs
and NHWAs with similar disease stages were compared and through mathematical modeling,
essentially matched on a proxy of cancer virulence, tumor grade, and on two strong correlates
of other chronic diseases, age and poverty. Therefore, the two groups seemed to be quite
similarly diseased, making comorbid alternative explanations unlikely.

Conclusions
Overall, AAs with non-localized colon cancer are 25% less likely to receive indicated
chemotherapy than are NHWAs with similar colon cancers. Among the extremely poor and
inadequately insured AAs are 60% less likely than NHWAs to receive such care. Ethnicity,
poverty and health insurance status appear to interact in such a way that the multiplicative
barriers to care of being extremely poor and inadequately insured are worse for AAs than
they are for NHWAs. AAs are more prevalently poor and inadequately insured, but even
when depth of income-based poverty is controlled, they still have substantially fewer assets
than NHWAs so they are probably much less able to absorb the indirect and direct, but
uncovered, costs of colon cancer care. Policy makers ought to be cognizant of these factors as
they roll out Obamacare and consider future reforms of health care in America.
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